The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis

QR Code

The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis

Silvia Migliaccio, Marina Brama, Giovanni SperaCattedra di Medicina Interna, Dipartimento di Fisiopatologia Medica, Università degli Studi di Roma “La Sapienza”, Italy Abstract: Osteoporosis is a skeletal metabolic disease characterized by a compromised bone fragility,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Silvia Migliaccio, Marina Brama, Giovanni Spera
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2007
Sujets:	Geriatrics RC952-954.6
Accès en ligne:	https://doaj.org/article/54dd43997e2a4ad9bab5ca08bb97a0fb
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Effect of estrogens on skin aging and the potential role of SERMs
par: Susan Stevenson, et autres
Publié: (2007)

Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
par: Luigi Gennari, et autres
Publié: (2010)

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
par: Esteban Jódar-Gimeno
Publié: (2007)

Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice
par: Oliver Bock, et autres
Publié: (2008)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
par: John Sunyecz
Publié: (2008)

Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates
par: Gu T, et autres
Publié: (2016)

Transdermal hormone therapy and bone health
par: Lee P Shulman
Publié: (2008)

Significant association between parathyroid hormone and uric acid level in men
par: Chin KY, et autres
Publié: (2015)

Update on bazedoxifene: A novel selective estrogen receptor modulator
par: Diane M Biskobing
Publié: (2007)

Teriparatide in the management of osteoporosis
par: Donald Bodenner, et autres
Publié: (2008)

Osteoporosis screening and risk management
par: Consuelo H Wilkins
Publié: (2007)

Clinical challenges in the management of osteoporosis
par: Sheryl F Vondracek, et autres
Publié: (2008)

Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
par: Cheng Q, et autres
Publié: (2018)

Osteoporosis in the aging male: Treatment options
par: Stephen P Tuck, et autres
Publié: (2008)

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
par: Raja Bobba, et autres
Publié: (2007)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
par: Richard Derman, et autres
Publié: (2009)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
par: Philip Sambrook
Publié: (2007)

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis
par: Mederle OA, et autres
Publié: (2018)

Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary
par: Alex Fisher, et autres
Publié: (2010)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
par: María J Moro-Álvarez, et autres
Publié: (2008)

Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies
par: Caffarelli C, et autres
Publié: (2017)

Editorial Foreword: Comments on "Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging" || FREE PAPER ||
par: Richard F Walker
Publié: (2008)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
par: Victoria J Sinibaldi
Publié: (2008)

Remodeling of t-system and proteins underlying excitation-contraction coupling in aging versus failing human heart
par: Yankun Lyu, et autres
Publié: (2021)

Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study
par: Flodin L, et autres
Publié: (2014)

Lifestyle and nutrition, caloric restriction, mitochondrial health and hormones: Scientific interventions for anti-aging
par: Luis Vitetta, et autres
Publié: (2008)

Upper limit of the normal range for thyrotropin-stimulating hormone is higher with increasing age [Corrigendum]
par: Jolobe OM
Publié: (2013)

Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal Osteoporosis
par: Liu Z, et autres
Publié: (2020)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
par: Fujiwara S, et autres
Publié: (2014)

Osteoporosis in men: epidemiology and treatment with denosumab
par: Sidlauskas KM, et autres
Publié: (2014)

Pharmacological treatment of osteoporosis in the oldest old
par: Vandenbroucke A, et autres
Publié: (2017)

Bone mineral density scans in veterans
par: Elizabeth Bass, et autres
Publié: (2007)

Is grand multiparity a risk factor for the development of postmenopausal osteoporosis?
par: Peker N, et autres
Publié: (2018)

Editorial: Primary Locus Intervention: A novel approach to treating age-associated hormone insufficiency ||Free Paper||
par: Richard F Walker
Publié: (2008)

Role of zoledronic acid in the prevention and treatment of osteoporosis
par: Räkel A, et autres
Publié: (2011)

Selective estrogen receptor modulators: tissue specificity and clinical utility
par: Martinkovich S, et autres
Publié: (2014)

A decrease in NAD+ contributes to the loss of osteoprogenitors and bone mass with aging
par: Ha-Neui Kim, et autres
Publié: (2021)

Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
par: Nagy EE, et autres
Publié: (2020)

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
par: Irene Lambrinoudaki, et autres
Publié: (2008)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
par: Paula Rackoff
Publié: (2009)